Respiration (physiology)

OrsoBio Announces Presentation of Five Abstracts at AASLD’s The Liver Meeting® 2022 Highlighting Programs for Severe Metabolic Disorders

Retrieved on: 
Thursday, November 3, 2022
Health, Infectious Diseases, Diabetes, Clinical Trials, Pharmaceutical, Biotechnology, Doctor of Philosophy, Abstract (summary), Associate, Research, Phase 1, 2021 Essex County Council election, Weight loss, Liver, Custom, Lipogenesis, Cincinnati, Respiration (physiology), Mouse, NASH, Safety, Pharmacokinetics, AMPK, IPSC, Non-alcoholic fatty liver disease, Northwest Hospital & Medical Center, Lipotoxicity, Liver X receptor, Patient, Institute of Liver and Biliary Sciences, TCA, AASLD, Pediatrics, Translation, Hepatocyte, Oxidative stress, Plasma, Dyslipidemia, Gilead Sciences, GCKR, De novo, DNL, Foundation, LDL, Tryptophan, Fatty liver disease, Center, Acquired generalized lipodystrophy, Lipid metabolism, Gene, Insulin resistance, Primate, ABCA1, MD, ABCG1, LXR, Pharmaceutical industry, Medical device, Vaccine, Dietary supplement, Rail profile

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced the presentation of five abstracts from the companys programs at AASLDs The Liver Meeting from November 4-8.

Key Points: 
  • OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced the presentation of five abstracts from the companys programs at AASLDs The Liver Meeting from November 4-8.
  • There remains tremendous unmet medical need for patients with severe metabolic disorders, said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio.
  • I am truly excited about translating the data on OrsoBios compounds in HLOs derived from genetic subsets of patients to clinical studies in patients with severe metabolic disorders.
  • The following abstracts will be presented as poster presentations at The Liver Meeting, in Washington, D.C., November 4-8, 2022.

ZENB ANNOUNCES MULTI-YEAR SPONSORSHIP WITH FC BARCELONA

Retrieved on: 
Friday, November 4, 2022
ZEN, Skin, Potassium, FC Barcelona, Nutrient, Seed, Athlete, Thought, Respiration (physiology), Official, Water, Iron, Nature, Phosphorus, Organization, Vegetable, Football, Plant, VIP, Pea, Partnership, Marketing, Carbon, Club, Pinterest, Meal, Flour, Dietary supplement, Facebook, Instagram

CHICAGO, Nov. 4, 2022 /PRNewswire/ -- Today, ZENB, the direct-to-consumer, plant-based food brand known for its whole-plant approach, announced a multi-year sponsorship of professional football club FC Barcelona. The brand will become the first Official Gluten-Free Food Partner of the club in the US, as more individuals look for inspiration to professional sports teams and athletes who prioritize high performance lifestyles fueled by clean-eating, often relying on the benefits of plant-forward diets.

Key Points: 
  • Through the sponsorship, ZENB aims to inspire people everywhere to fuel their lives with the goodness of nature.
  • "We are thrilled to welcome ZENB as the Official Gluten-Free Partner of FC Barcelona in the US," said Juli Guiu, Marketing Area Vice President, FC Barcelona.
  • Fans will be able to experience and learn more about ZENB through a wide range of product sampling activities, digital content, and other collaborations between ZENB and FC Barcelona.
  • To celebrate the launch of this partnership, ZENB is giving away a trip to Barcelona, complete with airfare, hotel and tickets to a FC Barcelona match.

Panavance Therapeutics to Present at BioFuture 2022

Retrieved on: 
Wednesday, November 2, 2022
AG, Pancreatic cancer, Population, CEO, Chemische Industrie Uithoorn, GLOBE, Trial of the century, Respiration (physiology), Melanoma, Company, Therapy, FDA, Ed, Patient, Ovarian cancer, Breast, Quality of life, Forward-looking statement, Pharmaceutical industry, Panaveli

BERWYN, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (Panavance or the Company), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic designed to disrupt cancers energy metabolism and improve quality of life for patients, today announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics will present on Tuesday, November 8, 2022 at 12:00 PM ET at BioFuture 2022 being held in New York, NY.

Key Points: 
  • BERWYN, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (Panavance or the Company), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic designed to disrupt cancers energy metabolism and improve quality of life for patients, today announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics will present on Tuesday, November 8, 2022 at 12:00 PM ET at BioFuture 2022 being held in New York, NY.
  • In addition to the presentation, members of the executive leadership team will be available for in person meetings.
  • Panavance Therapeutics Inc. is a privately-held, clinical-stage pharmaceutical company developing a novel oncology platform focused on improving the effectiveness of cancer treatments and quality of life for patients.
  • Forward-looking statements contained in this press release are made as of this date, and Panavance undertakes no duty to update such information except as required under applicable law.

OrsoBio Acquires Phase 2-Ready, Selective ACC2 Inhibitor from Shionogi & Co., Ltd. for the Treatment of Type 2 Diabetes

Retrieved on: 
Wednesday, November 2, 2022
Health, Diabetes, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, MACP, Liver, Heart, MD, Yale school, Health, Pain, Insulin resistance, Doctor of Philosophy, Shionogi, Hypertriglyceridemia, Type 2 diabetes, CNS, MACE, Program, Infection, Respiration (physiology), LDL, Thrombocytopenia, Yale School of Medicine, Safety, Institute of Liver and Biliary Sciences, FRCP, Cirrhosis, Fatty liver disease, Foundation, Abstract, Disorder, FAO, Pharmacokinetics, Patient, Organic acid, Poster, Mitochondrion, Gilead Sciences, Lipodystrophy, Dyslipidemia, Sarcopenia, Pharmaceutical industry, Medicine

TLC-3595 also has potential for treating other conditions characterized by impaired FAO, including cirrhosis with sarcopenia and genetic, long-chain FAO disorders.

Key Points: 
  • TLC-3595 also has potential for treating other conditions characterized by impaired FAO, including cirrhosis with sarcopenia and genetic, long-chain FAO disorders.
  • TLC-3595 treatment led to improvements in LDL and total cholesterol, confirming the compounds pharmacodynamic effects, and its pharmacokinetics support once daily oral administration.
  • Insulin resistance is the major predisposing factor in the pathogenesis of type 2 diabetes.
  • Selectively inhibiting ACC2 with TLC-3595 offers promise as a therapy for type 2 diabetes and other disorders characterized by impaired FAO.

OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals

Retrieved on: 
Wednesday, November 2, 2022
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Pharmacology, Entrepreneurship, Liver, MD, Lipogenesis, Plasma, Steatosis, ABCG1, Acquisition, Mouse, Liver disease, Hypertriglyceridemia, Lipoprotein, IPSC, Respiration (physiology), Institute of Liver and Biliary Sciences, NASH, Fatty liver disease, Foundation, DNL, Lipid metabolism, ABCA1, LXR, Patient, GCKR, De novo, Acquired generalized lipodystrophy, Gilead Sciences, Gene, Dyslipidemia, Cholesterol, Abstract (summary), Pharmaceutical industry, Gum arabic, Dietary supplement, Doctor of Philosophy, Liver X receptor, Rail profile

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of assets relating to the Liver X Receptor (LXR) inverse agonist program from Phenex Pharmaceuticals, including lead candidate TLC-2716 and associated intellectual property.

Key Points: 
  • OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of assets relating to the Liver X Receptor (LXR) inverse agonist program from Phenex Pharmaceuticals, including lead candidate TLC-2716 and associated intellectual property.
  • Our Phase 1 study is progressing well, and we look forward to the continued development of TLC-2716 for the treatment of severe dyslipidemias in 2023.
  • I am truly excited that OrsoBio is progressing TLC-2716 into the clinic to unlock the potential of this first-in-class compound for patients with severe dyslipidemias.
  • OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis.

OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company

Retrieved on: 
Wednesday, November 2, 2022
Health, Diabetes, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Pharmacology, Oxidative stress, Liver, MD, Steatosis, Lipotoxicity, Acquisition, Hepatocyte, Mouse, Doctor of Philosophy, Degenerative disease, Complementarity, Program, IPSC, Respiration (physiology), Chemistry, Institute of Liver and Biliary Sciences, Maintenance, Fatty liver disease, Rail profile, Foundation, Abstract, De novo synthesis, NAD, Patient, Poster, Biology, De novo, Gilead Sciences, Tryptophan, Dyslipidemia, Lipodystrophy, Pharmaceutical industry

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of an ACMSD inhibitor program from Mitobridge, an Astellas Company.

Key Points: 
  • OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of an ACMSD inhibitor program from Mitobridge, an Astellas Company.
  • The program includes a range of proprietary compounds being evaluated for their potential to address mitochondrial dysfunction in metabolic and inflammatory liver and kidney disorders.
  • ACMSD is highly expressed in the liver and kidneys and NAD+ is reduced in patients with advanced hepatic and renal disease.
  • TLC-065 and other compounds within the ACMSD inhibitor portfolio are being studied for their potential to replenish NAD+ and improve mitochondrial function.

OrsoBio Announces Exclusive License to Intellectual Property Relating to Mitochondrial Protonophores for the Treatment of Severe Metabolic Disorders

Retrieved on: 
Wednesday, November 2, 2022
Medical Supplies, Hospitals, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Oncology, Pharmacology, Weight loss, MACP, MD, Yale school, Insulin resistance, Doctor of Philosophy, MACE, Research, National Institute, Respiration (physiology), Yale School of Medicine, Safety, Dyslipidemia, FRCP, NASH, Kidney, DNP, Institute of Liver and Biliary Sciences, Fatty liver disease, Foundation, Patient, SBIR, National Institute of Diabetes and Digestive and Kidney Diseases, Small Business Innovation Research, Acquired generalized lipodystrophy, Gilead Sciences, CRMP, NIDDK, Digestive, Pharmaceutical industry, Yale University, IND, Medicine

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced that it has acquired exclusive worldwide rights to intellectual property from Yale University to enable the development of novel mitochondrial protonophores.

Key Points: 
  • OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced that it has acquired exclusive worldwide rights to intellectual property from Yale University to enable the development of novel mitochondrial protonophores.
  • The SBIR grant will enable OrsoBio to advance TLC-1235 as a potential treatment to improve insulin sensitivity, NASH, and dyslipidemia in patients with severe lipodystrophies.
  • TLC-1235 is a novel, controlled-release mitochondrial protonophore that has been shown to be both safe and effective in extensive preclinical models.
  • OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis.

OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders

Retrieved on: 
Wednesday, November 2, 2022
Health, Diabetes, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Weight loss, MACP, Liver, MD, Yale school, Plasma, Hepatocyte, Methanol toxicity, Insulin resistance, Doctor of Philosophy, Obesity, MACE, Intellectual property, Respiration (physiology), AMPK, Yale School of Medicine, Dyslipidemia, FRCP, NASH, Institute of Liver and Biliary Sciences, Fatty liver disease, Foundation, Abstract, Primate, Patient, Lipodystrophy, De novo, Gilead Sciences, TCA, Diabetes, Yale University, Pharmaceutical industry, Medicine

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced initiation of IND-enabling studies of TLC-6740, a liver-targeted mitochondrial protonophore.

Key Points: 
  • OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced initiation of IND-enabling studies of TLC-6740, a liver-targeted mitochondrial protonophore.
  • TLC-6740 will be initially advanced for the treatment of patients with severe lipodystrophies with a first-in-human study planned to initiate in 2023.
  • TLC-6740 is a novel, liver-targeted mitochondrial protonophore in development for the treatment of severe lipodystrophies and other metabolic disorders.
  • OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis.

OrsoBio Launches to Develop Novel Therapies for Patients with Severe Metabolic Disorders

Retrieved on: 
Tuesday, November 1, 2022
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Liver, MD, HLO, CEO, Stanford University, American Association for the Study of Liver Diseases, Doctor of Philosophy, Aminocarboxymuconate-semialdehyde decarboxylase, Liver X receptor, Hypertriglyceridemia, Partner, Industry, Intellectual property, Respiration (physiology), Northwest Hospital & Medical Center, American Association, Institute of Liver and Biliary Sciences, NASH, Cincinnati, Fatty liver disease, Metabolism, LXR, NAD, Patient, Therapy, Gilead Sciences, Lipodystrophy, Tryptophan, Dyslipidemia, Phase 1, Diabetes, Yale University, Association, Pharmaceutical industry, Medical imaging, DRS, Shionogi, Astellas Pharma, Immunology

OrsoBio has initiated preclinical and clinical activities to support advancement of these compounds for the treatment of patients with severe metabolic disorders, including diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis (NASH).

Key Points: 
  • OrsoBio has initiated preclinical and clinical activities to support advancement of these compounds for the treatment of patients with severe metabolic disorders, including diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis (NASH).
  • Our programs address the root causes of metabolic dysregulation in patients with severe metabolic disorders, said Mani Subramanian, MD, PhD, Founder and CEO of OrsoBio.
  • The OrsoBio approach of targeting multiple fundamental aspects of cellular energetics addresses large unmet patient need in severe metabolic diseases.
  • OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis.

Nature's Bounty Calls on All Canadians to See What Our Beans Are Full Of with The Newly Launched VitaBeans Supplements

Retrieved on: 
Tuesday, October 25, 2022
Innovation, Vitamin B12, Taste, New natural law, Vitamin, Marketing, Vitamin D, Antioxidant, Supplement, SKIN, Biotin, Immune system, Mineral, Zinc, Respiration (physiology), HAIR, NEW, Health, HSN, Amusement arcade, Dietary supplement, Iodine

"NATURE'S BOUNTY is thrilled to be bringing a unique and innovative way for Canadians to get their daily vitamins, with our VITABEANS being the first of their kind in Canada.

Key Points: 
  • "NATURE'S BOUNTY is thrilled to be bringing a unique and innovative way for Canadians to get their daily vitamins, with our VITABEANS being the first of their kind in Canada.
  • We've got you covered with NATURE'S BOUNTY VITABEANS," says Julie-Anne McCallum, Senior Director of Marketing and Innovation at NATURE'S BOUNTY.
  • Simply pick the VITABEANS that align with one's needs:
    NATURE'S BOUNTY SLEEP VITABEANS: Made with melatonin to help reset the body's sleep wake cycle.
  • NATURE'S BOUNTY ENERGY VITABEANS: Support the body's energy metabolism with Vitamin B12 in a bean that tastes like sweet cherry.